http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-111840558-A
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_18f4b13b863327ab144da2ed26a333a1 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-436 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P11-00 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-436 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-00 |
| filingDate | 2020-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3927563bd90c4beceed3c04037316611 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9b106d11497115acc84a738af430eb74 |
| publicationDate | 2020-10-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-111840558-A |
| titleOfInvention | Application of mitochondria in the preparation of drugs for the treatment of new coronary pneumonia |
| abstract | The invention belongs to the field of biomedicine, and particularly relates to the application of mitochondria in the preparation of medicines for the treatment of new coronary pneumonia, in order to find a new immunotherapy scheme for the comprehensive treatment of new coronary pneumonia, the invention is effective for the treatment of active new coronary pneumonia patients with peripheral blood lymphocytes. Mitochondria studies have found that the membrane permeability of mitochondria in lymphocytes of patients with new coronary pneumonia is abnormal, triggering the activation of downstream related apoptosis signaling pathways, resulting in excessive apoptosis of immune regulation-related specific cells, suggesting that mitochondria-related trigger apoptosis The intervention of the signaling pathway is expected to be applied in the comprehensive treatment of new coronary pneumonia, and the preparation of drugs for the treatment of new coronary pneumonia can reduce the severity of the disease and reduce the mortality rate of patients with new coronary pneumonia, and ultimately achieve the purpose of cellular immunotherapy. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-113521285-A |
| priorityDate | 2020-06-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 43.